公开(公告)号：US20150219667A1

公开(公告)日：2015-08-06

申请号：US14614998

申请日：2015-02-05

申请人： Emmanuel Zorn

发明人： Emmanuel Zorn

IPC分类号： G01N33/68 ,  A61M1/34

CPC分类号： G01N33/6854 ,  A61M2202/0021 ,  A61M2202/0417 ,  G01N2510/00 ,  G01N2800/245 ,  G01N2800/50

摘要： It has been discovered that significantly elevated levels of anti-apoptotic cell IgG is an important contributor to and predictor of late graft rejection. Kaplan-Meier survival analysis revealed that patients with high pre-transplant IgG and post-transplant reactivity to apoptotic cells had a significantly increased rate of late graft loss that was apparent after approximately 1 year post-transplant. This association between pre-transplant IgG reactivity to apoptotic cells and graft loss was still significant after excluding patients with high reactivity to HLA, and it was almost exclusively mediated by IgG1 and IgG3 with complement fixing and activating properties. The association between elevated levels of anti-apoptotic cell IgG antibodies and late transplant rejection forms a basis for diagnosing and treating patients at high risk of late transplant rejection.

摘要翻译： 已经发现，抗凋亡细胞IgG水平显着升高是晚期移植排斥反应的重要贡献和预测因子。 Kaplan-Meier生存分析显示，移植前高IgG和移植后对凋亡细胞的反应性的患者在移植后大约1年后明显增加晚期移植物丢失率。 排除移植后IgG对细胞凋亡的反应和移植物损失之间的关联在排除HLA高反应性的患者后仍然显着，并且几乎完全由具有补体固定和活化性质的IgG1和IgG3介导。 抗凋亡细胞IgG抗体水平升高与晚期移植排斥反应之间的联系形成诊断和治疗晚期移植排斥高风险患者的基础。

公开(公告)号：US06231536B1

公开(公告)日：2001-05-15

申请号：US09316226

申请日：1999-05-21

申请人： M. Rigdon Lentz

发明人： M. Rigdon Lentz

IPC分类号： A61M3700

CPC分类号： A61K35/14 ,  A61K31/00 ,  A61K31/337 ,  A61K31/454 ,  A61K31/555 ,  A61K31/704 ,  A61K35/16 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K41/00 ,  A61K41/0019 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3681 ,  A61M2202/0417 ,  A61M2205/50 ,  A61M2205/75 ,  A61N5/1028 ,  B01D15/00 ,  B01D29/50 ,  B01D37/00 ,  B01D61/02 ,  A61K2300/00

摘要： A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

摘要翻译： 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

公开(公告)号：US20230338628A1

公开(公告)日：2023-10-26

申请号：US18215498

申请日：2023-06-28

申请人： Astaria Global, LLC

发明人： David J. Lutz ,  William J. Cramer ,  Michael D. Duvall ,  Robert S. Shoemaker

IPC分类号： A61M1/02 ,  B01L3/00 ,  A61K35/16 ,  A61J1/20 ,  A61K38/17 ,  A61K38/57

CPC分类号： A61M1/029 ,  B01L3/5021 ,  B01L3/50825 ,  A61K35/16 ,  A61J1/2096 ,  A61J1/2082 ,  A61J1/2062 ,  A61J1/201 ,  A61K38/1722 ,  A61K38/57 ,  A61M2202/0417 ,  B01L2400/0478 ,  B01L2400/0409 ,  B01L2300/0832

摘要： A method includes: depositing whole blood into at least one separator tube; subjecting the at least one separator tube to a first centrifugal force to cause a combination of the first centrifugal force and separator gel within each separator tube of the at least one separator tube to separate plasma of the whole blood from red and white blood cells of the whole blood within the at least one separator tube, wherein the plasma includes α2M molecules; transferring one or more portions of the plasma from within the at least one separator tube and into at least one isolator; and subjecting the at least one isolator to a second centrifugal force to cause a combination of the second centrifugal force and a filter within each isolator of the at least one isolator to isolate the α2M molecules from other components of the plasma within the at least one isolator.

公开(公告)号：US20150231178A1

公开(公告)日：2015-08-20

申请号：US14498605

申请日：2014-09-26

申请人： M. Rigdon Lentz

发明人： M. Rigdon Lentz

IPC分类号： A61K35/14 ,  A61N5/10 ,  A61M1/36 ,  A61K35/16 ,  A61K31/454

CPC分类号： A61K35/14 ,  A61K31/00 ,  A61K31/337 ,  A61K31/454 ,  A61K31/555 ,  A61K31/704 ,  A61K35/16 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K41/00 ,  A61K41/0019 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3603 ,  A61M1/3681 ,  A61M2202/0417 ,  A61M2205/50 ,  A61M2205/75 ,  A61N5/10 ,  A61N5/1028 ,  B01D15/00 ,  B01D29/50 ,  B01D37/00 ,  B01D61/02 ,  A61K2300/00

摘要： A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

摘要翻译： 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

公开(公告)号：US20090112146A1

公开(公告)日：2009-04-30

申请号：US11928881

申请日：2007-10-30

申请人： Mary Lou Wratten ,  Mauro Atti ,  Antonio Santoro

发明人： Mary Lou Wratten ,  Mauro Atti ,  Antonio Santoro

IPC分类号： A61M1/36

CPC分类号： A61M1/3472 ,  A61M1/3486 ,  A61M1/3679 ,  A61M2202/0417 ,  A61M2202/0445

摘要： Circulating free lambda and kappa free light chains in blood play a role in the pathogenesis of acute renal failure due to myeloma. Coupled plasma filtration and adsorption allows separation of plasma from blood and treatment of the plasma through a cartridge containing a sorbent or resin material, such as hydrophobic divinylbenzene styrenic resins having an average bead diameter of 75 microns, an average pore diameter of 30 nm, and a surface area of 700 m2/g. Lambda and kappa free light chain concentrations progressively decrease during coupled plasma filtration and adsorption treatment resulting in significant reductions by the end of the treatment.

摘要翻译： 在血液中循环游离的λ和κ免费轻链在骨髓瘤引起的急性肾衰竭的发病机理中起作用。 耦合的等离子体过滤和吸附允许将血浆与血液分离并通过包含吸附剂或树脂材料的药筒（例如平均珠粒直径为75微米，平均孔径为30nm的疏水性二乙烯基苯苯乙烯类树脂）以及 表面积为700平方米/克。 在耦合等离子体过滤和吸附处理期间，λ和κ无关轻链浓度逐渐降低，导致治疗结束时显着降低。

公开(公告)号：US11833279B2

公开(公告)日：2023-12-05

申请号：US17837090

申请日：2022-06-10

申请人： Astaria Global, LLC

发明人： David J. Lutz ,  William J. Cramer ,  Michael D. Duvall ,  Robert S. Shoemaker

IPC分类号： A61M1/02 ,  B01L3/00 ,  A61K35/16 ,  A61J1/20 ,  A61K38/17 ,  A61K38/57

CPC分类号： A61M1/029 ,  A61J1/201 ,  A61J1/2062 ,  A61J1/2082 ,  A61J1/2096 ,  A61K35/16 ,  A61K38/1722 ,  A61K38/57 ,  B01L3/5021 ,  B01L3/50825 ,  A61M2202/0417 ,  B01L2300/0832 ,  B01L2400/0409 ,  B01L2400/0478

摘要： A method includes: depositing whole blood into at least one separator tube; subjecting the at least one separator tube to a first centrifugal force to cause a combination of the first centrifugal force and separator gel within each separator tube of the at least one separator tube to separate plasma of the whole blood from red and white blood cells of the whole blood within the at least one separator tube, wherein the plasma includes α2M molecules; transferring one or more portions of the plasma from within the at least one separator tube and into at least one isolator; and subjecting the at least one isolator to a second centrifugal force to cause a combination of the second centrifugal force and a filter within each isolator of the at least one isolator to isolate the α2M molecules from other components of the plasma within the at least one isolator.

公开(公告)号：US20130071350A1

公开(公告)日：2013-03-21

申请号：US13570876

申请日：2012-08-09

申请人： M. Rigdon Lentz

发明人： M. Rigdon Lentz

IPC分类号： A61K35/14 ,  B01D15/00 ,  B01D29/50 ,  A61K31/454 ,  A61M1/36 ,  A61N5/10 ,  A61K35/16 ,  B01D61/02 ,  B01D37/00

CPC分类号： A61K35/14 ,  A61K31/00 ,  A61K31/337 ,  A61K31/454 ,  A61K31/555 ,  A61K31/704 ,  A61K35/16 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K41/00 ,  A61K41/0019 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3603 ,  A61M1/3681 ,  A61M2202/0417 ,  A61M2205/50 ,  A61M2205/75 ,  A61N5/10 ,  A61N5/1028 ,  B01D15/00 ,  B01D29/50 ,  B01D37/00 ,  B01D61/02 ,  A61K2300/00

摘要： The present invention refers to a system for inducing an immune response against transformed, infected, or diseased tissue comprising a device for removing only components present in blood or plasma having a molecular weight of 120,000 daltons or less, having an inlet and outlet for connection to a pump and tubing to recirculate the blood or plasma of a patient through the device. Further, the present invention refers to methods of inducing an immune response against transformed, infected, or diseased tissue comprising administering to a patient blood, plasma, or a blood fraction from which only components having a molecular weight of 120,000 daltons or less have been removed, whereby administration of said blood, plasma, or blood fraction induces an immune response against transformed, infected, or diseased tissue in the patient until the transformed, infected, or diseased tissue is reduced in amount.

摘要翻译： 本发明涉及用于诱导针对转化，感染或患病组织的免疫应答的系统，其包括用于仅去除分子量为120,000道尔顿或更少的血液或血浆中存在的成分的装置，其具有用于连接到 泵和管道，以使患者的血液或血浆再循环通过装置。 此外，本发明涉及诱导针对转化，感染或患病组织的免疫应答的方法，包括向患者施用血液，血浆或血液级分，其中只除去分子量为120,000道尔顿或更少的组分已被除去 由此所述血液，血浆或血液成分的给药对患者中的转化，感染或患病组织诱导免疫应答，直到转化，感染或患病组织的量减少。

公开(公告)号：US20100285044A1

公开(公告)日：2010-11-11

申请号：US12685307

申请日：2010-01-11

申请人： M. Rigdon Lentz

发明人： M. Rigdon Lentz

IPC分类号： A61K39/00 ,  A61M1/34 ,  A61M37/00 ,  A01N1/02 ,  A61K38/18 ,  A61K31/454

CPC分类号： A61K35/14 ,  A61K31/00 ,  A61K31/337 ,  A61K31/454 ,  A61K31/555 ,  A61K31/704 ,  A61K35/16 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K41/00 ,  A61K41/0019 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3603 ,  A61M1/3681 ,  A61M2202/0417 ,  A61M2205/50 ,  A61M2205/75 ,  A61N5/10 ,  A61N5/1028 ,  B01D15/00 ,  B01D29/50 ,  B01D37/00 ,  B01D61/02 ,  A61K2300/00

摘要： A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

摘要翻译： 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

公开(公告)号：US20080057060A1

公开(公告)日：2008-03-06

申请号：US11929340

申请日：2007-10-30

申请人： M. Lentz

发明人： M. Lentz

IPC分类号： A61K39/395 ,  A61P37/04

CPC分类号： A61K31/00 ,  A61K31/337 ,  A61K31/555 ,  A61K31/704 ,  A61K41/00 ,  A61K41/0019 ,  A61K2039/505 ,  A61M1/34 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3468 ,  A61M1/3472 ,  A61M1/3482 ,  A61M1/3496 ,  A61M2202/0417 ,  C07K16/2878 ,  C07K2317/76

摘要： A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation.

摘要翻译： 一种治疗癌症的方法是使用超级血液分离法，精制以除去小于120,000道尔顿分子量的化合物，然后施用替代液，以刺激患者的免疫系统攻击实体瘤。 在优选实施例中，使用孔径为0.02至0.05微米，分子量截留值为120,000道尔顿的毛细管超滤器将患者超薄，足以过滤一个血液体积。 优选的替代液体是超分离的正常血浆。 患者优选每天治疗三周，进行诊断测试以证实肿瘤已经收缩，然后重复治疗方案。 治疗优选与替代疗法组合，例如用抗血管生成化合物，一种或多种细胞因子如TNF，γ干扰素或IL-2或促凝血剂化合物的治疗。 治疗增加内源性，局部水平的细胞因子，如TNF。 当提供增强细胞因子对肿瘤活性的治疗，例如使用烷化剂，多柔比星，卡铂，顺铂和紫杉醇的治疗时，这提供了改善效果的基础。 或者，超单位治疗可以与局部化疗，全身化学疗法和/或辐射结合。

公开(公告)号：US6133431A

公开(公告)日：2000-10-17

申请号：US117233

申请日：1998-10-20

申请人： Takamune Yasuda ,  Osamu Odawara ,  Eiji Ogino ,  Michio Nomura ,  Takahisa Nakai ,  Takashi Asahi ,  Nobutaka Tani

发明人： Takamune Yasuda ,  Osamu Odawara ,  Eiji Ogino ,  Michio Nomura ,  Takahisa Nakai ,  Takashi Asahi ,  Nobutaka Tani

IPC分类号： A61K35/14 ,  A61M1/36 ,  B01J20/32 ,  C07K17/00 ,  C07K17/02 ,  A61K39/00

CPC分类号： C07K17/02 ,  B01J20/3204 ,  B01J20/321 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3274 ,  B01J20/3282 ,  C07K17/00 ,  A61M1/3679 ,  A61M2202/0417

摘要： An adsorbent that exhibits a high specificity in adsorbing immunoglobulins and/or complexes thereof, is extremely reduced in the lowering of the adsorption characteristic during sterilization or storage, is highly stable and safe, and is prepared by immobilizing on a water-insoluble support either a peptide derivative which has undergone at least one of the deletion, substitution, insertion, or addition of amino acids in a peptide having a specified amino acid sequence or an amino acid sequence, or the above peptide derivative which has undergone the addition of Lyn or Cys at the amino and/or carboxyl terminal thereof; a device for adsorption and removal made by packing the adsorbent in a vessel equipped with effluent preventing means; and a method of adsorbing and removing immunoglobulins and/or complexes thereof contained in the blood, plasma or other body fluids with the adsorbent.

摘要翻译： PCT No.PCT / JP97 / 00161 Sec。 371日期：1998年10月20日 102（e）日期1998年10月20日PCT 1997年1月24日PCT公布。 第WO97 / 26930号公报 日期1997年7月31日在吸附免疫球蛋白和/或其复合物中显示高特异性的吸附剂在灭菌或储存期间吸附特性的降低极度降低，是高度稳定和安全的，并且通过固定在水上制备 - 不溶性支持已经在具有特定氨基酸序列或氨基酸序列的肽中经历了氨基酸的缺失，取代，插入或添加中的至少一个的肽衍生物，或上述已经经历 在其氨基和/或羧基末端添加Lyn或Cys; 用于通过将吸附剂包装在装有流出物防止装置的容器中而进行吸附和除去的装置; 以及利用吸附剂吸收和除去血液，血浆或其他体液中所含的免疫球蛋白和/或其复合物的方法。